Nuvalent, Inc. (NUVL) is a cutting-edge biopharmaceutical company focused on developing innovative therapies to target cancer. As with any investment, it is important to conduct a thorough technical analysis to assess the potential risks and rewards associated with investing in NUVL stock. Technical analysis involves studying historical price and volume data, as well as analyzing various technical indicators to gain insights into the stock's future direction.

One commonly used technical indicator is the Relative Strength Index (RSI), which measures the speed and change of price movements. The RSI can help identify overbought and oversold conditions, indicating potential buying or selling opportunities. Another useful indicator is the Average Directional Index (ADX), which measures the strength of a stock's trend. A high ADX value suggests a strong trend, while a low value indicates a weak trend.

Nuvalent (NUVL) Technical Analysis

This page provides a detailed technical analysis of Nuvalent, Inc. (NUVL) stock using various indicators such as RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Gain insights into the stock's performance and make informed investment decisions. Stay updated with Nuvalent's market trends and potential opportunities.

NUVL Technical Analysis: RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase ½ clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is ongoing IND-enabling studies. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	66.12	Neutral	266.2%
auto_graphMACD	2.36	Neutral	-33.6%
auto_graphCCI	220.76	Sell	81.0%
auto_graphADX	20.83	Neutral	-31.0%
auto_graphATR	5.70	Buy	-
auto_graphWILLR	-7.86	Sell	122.6%
auto_graphROC	39.17	Neutral	-24.7%
auto_graphSTOCHRSI	100.00	Sell	-47.0%

Buy	1	-87.50%
Hold	4	-50.00%
Sell	3	-62.50%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Nuvalent (NUVL) Technical Analysis

Keep an eye on Nuvalent

Frequently Asked Questions

What are the technical signals for Nuvalent (NUVL) stock based on the last 30 days?

Take Your Investments to a Whole New Level